Cancer Research UK will fund, sponsor and conduct the first-in-human Phase 1/2a clinical trial of Aleta’s CAR-T cell engager candidate, ALETA-001.
ALETA-001 is part of Aleta’s pipeline of therapies targeting blood cancers and solid tumours. It is being developed to treat people with B-cell lymphoma and leukaemia whose disease has progressed after receiving CD19 CAR-T cell therapy. If brought to market, ALETA-001 could offer another therapy for patients with limited treatment options.
